266. Familial mediterranean fever
27 clinical trials,   23 drugs   (DrugBank: 6 drugs),   14 drug target genes,   57 drug target pathways

Searched query = "Familial mediterranean fever"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000032557
2018/09/0130/05/2018An open-label continuation trial of tocilizumab for familial Mediterranean fever with colchicine ineffective or intoleranceAn open-label continuation trial of tocilizumab for familial Mediterranean fever with colchicine ineffective or intolerance - An open-label continuation trial of tocilizumab for familial Mediterranean fever familial Mediterranean feverTocilizumabDepartment of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical SciencesNULLComplete: follow-up continuing12years-oldNot applicableMale and Female24Not selectedJapan
2NCT03446209
(ClinicalTrials.gov)
April 23, 201811/12/2017Tocilizumab for the Treatment of Familial Mediterranean FeverTocilizumab for the Treatment of Familial Mediterranean Fever - A Randomized, Doubleblind, Phase II Proof of Concept StudyFamilial Mediterranean FeverDrug: Tocilizumab Infusion RoAcemtra (EU);Drug: 0.9% physiological salineUniversity Hospital TuebingenNULLCompleted18 Years64 YearsAll30Phase 2Germany
3JPRN-UMIN000028010
2018/03/0107/07/2017Randomized, double-blind, parallel group comparison trial of Tocilizumab for colchicine-resistant familial Mediterranean feverRandomized, double-blind, parallel group comparison trial of Tocilizumab for colchicine-resistant familial Mediterranean fever - Clinical trial of Tocilizumab for colchicine-resistant familial Mediterranean fever familial Mediterranean feverTocilizumab
Placebo
Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical SciencesNULLComplete: follow-up complete12years-oldNot applicableMale and Female24Not selectedJapan
4EUCTR2016-004505-13-DE
(EUCTR)
27/11/201721/08/2017Tocilizumab for the Treatment of Familial Mediterranean FeverTocilizumab for the Treatment of Familial Mediterranean Fever – A randomized, doubleblind, phase II proof of concept study-TOFFIFE - Tocilizumab for the Treatment of Familial Mediterranean Fever Adult patients with Familial Mediterranean Fever, who have active disease
MedDRA version: 20.0;Level: PT;Classification code 10016207;Term: Familial mediterranean fever;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: RoActemra® 20mg/ml Konzentrat
INN or Proposed INN: INN-Tocilizumab
Other descriptive name: TOCILIZUMAB
University Hospital TuebingenNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
30Phase 2Germany